CA2431747A1 - Traitement du dysfonctionnement sexuel male - Google Patents

Traitement du dysfonctionnement sexuel male Download PDF

Info

Publication number
CA2431747A1
CA2431747A1 CA002431747A CA2431747A CA2431747A1 CA 2431747 A1 CA2431747 A1 CA 2431747A1 CA 002431747 A CA002431747 A CA 002431747A CA 2431747 A CA2431747 A CA 2431747A CA 2431747 A1 CA2431747 A1 CA 2431747A1
Authority
CA
Canada
Prior art keywords
npy
agent
med
inhibitor
npyi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002431747A
Other languages
English (en)
Inventor
Alasdair Mark Naylor
Pieter Hadewijn Van Der Graaf
Christopher Peter Wayman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0030647A external-priority patent/GB0030647D0/en
Priority claimed from GB0108730A external-priority patent/GB0108730D0/en
Priority claimed from GB0109910A external-priority patent/GB0109910D0/en
Priority claimed from GB0111037A external-priority patent/GB0111037D0/en
Priority claimed from US09/895,367 external-priority patent/US20020028799A1/en
Priority claimed from US09/905,846 external-priority patent/US6878529B2/en
Priority claimed from GB0120679A external-priority patent/GB0120679D0/en
Application filed by Individual filed Critical Individual
Publication of CA2431747A1 publication Critical patent/CA2431747A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/344—Disorders of the penis and the scrotum and erectile dysfuncrion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur l'utilisation d'un inhibiteur d'un neuropeptide Y (NPY), de préférence d'un récepteur de NPY Y1, cet inhibiteur étant sélectif pour un récepteur de NPY ou NPY Y1 associé aux organes génitaux mâles, dans la préparation/fabrication d'un médicament destiné à être utilisé dans le traitement ou la prévention de la dysérection.
CA002431747A 2000-12-15 2001-12-10 Traitement du dysfonctionnement sexuel male Abandoned CA2431747A1 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
GB0030647.2 2000-12-15
GB0030647A GB0030647D0 (en) 2000-12-15 2000-12-15 Treatment of male sexual dysfunction
GB0108730A GB0108730D0 (en) 2001-04-06 2001-04-06 Treatment of male sexual dysfunction
GB0108730.3 2001-04-06
GB0109910A GB0109910D0 (en) 2001-04-23 2001-04-23 Treatment of sexual dysfunction
GB0109910.0 2001-04-23
GB0111037A GB0111037D0 (en) 2001-05-04 2001-05-04 Treatment of sexual dysfunction
GB0111037.8 2001-05-04
US09/895,367 2001-06-29
US09/895,367 US20020028799A1 (en) 2000-07-06 2001-06-29 Treatment of male sexual dysfunction
US09/905,846 2001-07-13
US09/905,846 US6878529B2 (en) 2000-07-14 2001-07-13 Compounds for the treatment of sexual dysfunction
GB0120679.6 2001-08-24
GB0120679A GB0120679D0 (en) 2001-08-24 2001-08-24 Treatment of male sexual dysfunction
PCT/IB2001/002399 WO2002047670A1 (fr) 2000-12-15 2001-12-10 Traitement du dysfonctionnement sexuel male

Publications (1)

Publication Number Publication Date
CA2431747A1 true CA2431747A1 (fr) 2002-06-20

Family

ID=27562581

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002431747A Abandoned CA2431747A1 (fr) 2000-12-15 2001-12-10 Traitement du dysfonctionnement sexuel male

Country Status (9)

Country Link
EP (1) EP1347750A1 (fr)
JP (1) JP2004522720A (fr)
CN (1) CN1496254A (fr)
AU (1) AU2002220977A1 (fr)
CA (1) CA2431747A1 (fr)
HU (1) HUP0400528A2 (fr)
IL (1) IL155775A0 (fr)
NZ (1) NZ526925A (fr)
WO (1) WO2002047670A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784327B2 (en) 1999-11-19 2006-03-09 Abbvie B.V. Human enzymes of the metalloprotease family
WO2003013571A1 (fr) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetiques de metallopeptides biologiquement actifs
WO2005000217A2 (fr) * 2003-06-06 2005-01-06 Merck & Co., Inc. Polytherapie permettant de traiter la dyslipidemie
EP1925307A1 (fr) * 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
US8101371B2 (en) 2007-10-18 2012-01-24 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
DE102009018668A1 (de) 2009-04-23 2010-11-25 Igor Lier Faltbare Duschkabine
ES2660772T3 (es) * 2010-11-15 2018-03-26 Neuroderm Ltd Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello
CN111840508A (zh) * 2020-07-17 2020-10-30 北京清大赛尔生物科技有限公司 一种预防及治疗男性性功能障碍的外用制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7580998A (en) * 1997-05-21 1998-12-11 Eli Lilly And Company 3-arylpropylamino neuropeptide y receptor antagonists
IL139455A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
AU4929601A (en) * 2000-03-23 2001-10-03 Merck & Co Inc Substituted piperidines as melanocortin receptor agonists
WO2001085173A1 (fr) * 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Derives d'alkylamine d'antagonistes de dihydropyridine npy
US6444675B2 (en) * 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6432960B2 (en) * 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists

Also Published As

Publication number Publication date
IL155775A0 (en) 2003-12-23
AU2002220977A1 (en) 2002-06-24
EP1347750A1 (fr) 2003-10-01
CN1496254A (zh) 2004-05-12
HUP0400528A2 (hu) 2004-06-28
NZ526925A (en) 2005-03-24
JP2004522720A (ja) 2004-07-29
WO2002047670A1 (fr) 2002-06-20

Similar Documents

Publication Publication Date Title
US20020028799A1 (en) Treatment of male sexual dysfunction
US20030119714A1 (en) Treatment of male sexual dysfunction
SK16722000A3 (sk) Zlúčeniny na liečenie sexuálnej dysfunkcie u žien
JP2008266338A (ja) 性機能障害を治療するための選択的ドーパミンｄ３受容体アゴニスト
CA2431747A1 (fr) Traitement du dysfonctionnement sexuel male
US20150072995A1 (en) Treatment of male sexual dysfunction
ZA200304460B (en) Treatment of male sexual dysfunction.
AU2005201482A1 (en) Compounds for the treatment of female sexual dysfunction
WO2002017963A2 (fr) Composition pharmaceutique
US20050020547A1 (en) Compounds for the treatment of female sexual dysfunction
US20040185094A1 (en) Pharmaceutical
KR100829262B1 (ko) 수컷의 성 기능 부전을 치료하는 방법
KR20030061441A (ko) 남성 성기능 장애의 치료
AU2003201471A1 (en) Treatment of male sexual dysfunction
ZA200300120B (en) Treatment of Male sexual dysfunction.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued